Home Supplements How We Rate Blog
Vaccinium macrocarpon

Cranberry Extract

Research reviewed: Up until 03/2026

Cranberry Extract (Vaccinium macrocarpon) is a dietary supplement with 5 published peer-reviewed studies involving 15,000 participants, researched for UTI Prevention.

5
Studies
15,000
Participants
2005–2023
Research Span

Evidence at a Glance

Strength is scored by study design, sample size, study type, and outcomes

Overall: Strong Evidence

UTI Prevention

Moderate
5 studies 2 of 5 positive 13,698 participants 4 human

Research Visualised

Visual breakdown of the clinical data.

Study Quality Breakdown

What types of studies were conducted

2/5
Randomised
2/5
Double-Blind
2/5
Placebo-Controlled

Participants Per Study

Larger samples = more reliable results

Study 1 (2023)
8,857
Study 2 (2017)
4,473
Study 3 (2020)
312
Study 4 (2005)
0
Study 5 (2015)
56

Research Timeline

When the studies were published

1
2005
1
2015
1
2017
1
2020
1
2023

All Studies

Detailed breakdown of each trial. Click to expand.

UTI Prevention

1

To assess cranberry products for preventing urinary tract infections (50 RCTs).

2023 8857 participants Up to 12 months Various cranberry products standardised by proanthocyanidin ...
Human Study Positive

Study Type

Cochrane systematic review and meta-analysis

Purpose

To assess cranberry products for preventing urinary tract infections (50 RCTs).

Dose

Various cranberry products standardised by proanthocyanidin (PAC) content

Participants

8857 participants across 50 studies

Duration

Up to 12 months

Results

Cranberry products significantly reduce risk of symptomatic, culture-verified UTIs in women with recurrent UTIs, children, and high-risk individuals. PAC-standardised extracts most effective.

How They Measured It

Symptomatic culture-verified UTI incidence, recurrence rates across RCTs

Read full study
2

To evaluate whether cranberry products reduce UTI incidence.

2017 4473 participants Various Various cranberry products
Human Study Positive

Study Type

Systematic review and meta-analysis

Purpose

To evaluate whether cranberry products reduce UTI incidence.

Dose

Various cranberry products

Participants

4473 participants across multiple RCTs

Duration

Various

Results

Cranberry ingestion significantly decreases UTI incidence (26-35% reduction) in susceptible populations. Higher PAC doses (36mg+) most effective. Evidence supports use in recurrent UTI patients.

How They Measured It

UTI incidence rate ratios, relative risk reductions

Read full study
3

To compare high vs low dose cranberry PAC extract for UTI prevention in healthy women.

2020 312 participants 24 weeks High dose: 72mg PAC vs low dose: 18mg PAC daily
Human Study RCT Double-Blind Placebo Positive

Study Type

Randomised, double-blind, placebo-controlled

Purpose

To compare high vs low dose cranberry PAC extract for UTI prevention in healthy women.

Dose

High dose: 72mg PAC vs low dose: 18mg PAC daily

Participants

312 healthy women with recurrent UTIs

Duration

24 weeks

Results

Higher PAC dose (72mg) significantly more effective than low dose. 26% reduction in UTI episodes. Clear dose-dependent relationship confirmed.

How They Measured It

Symptomatic UTI episodes, culture-confirmed infections, safety

Read full study
4

To characterize how cranberry A-type PACs prevent bacterial adhesion to uroepithelium.

2005 ? participants N/A N/A - mechanistic study
In Vitro Mixed

Study Type

Mechanistic study

Purpose

To characterize how cranberry A-type PACs prevent bacterial adhesion to uroepithelium.

Dose

N/A - mechanistic study

Participants

Cell and in vitro models

Duration

N/A

Results

A-type proanthocyanidins uniquely inhibit type P fimbriae-mediated adhesion of E. coli to uroepithelial cells at clinically achievable concentrations. Core UTI prevention mechanism confirmed.

How They Measured It

E. coli adhesion assays, P-fimbriae expression, in vitro uroepithelial models

Read full study
5

To assess cranberry extract on cardiovascular risk factors in metabolic syndrome.

2015 56 participants 8 weeks Cranberry extract 500mg daily
Human Study RCT Double-Blind Placebo Positive

Study Type

Randomised, double-blind, placebo-controlled

Purpose

To assess cranberry extract on cardiovascular risk factors in metabolic syndrome.

Dose

Cranberry extract 500mg daily

Participants

56 subjects with metabolic syndrome

Duration

8 weeks

Results

Significant improvement in HDL cholesterol, systolic blood pressure, and oxidative stress markers. CRP reduced. Multiple cardiovascular risk factors improved.

How They Measured It

HDL, LDL, total cholesterol, blood pressure, oxidative stress, CRP

Read full study

Frequently Asked Questions

Common questions about Cranberry Extract research

What does the research say about Cranberry Extract?

There are currently 120 peer-reviewed studies on Cranberry Extract (Vaccinium macrocarpon), involving 15,000 total participants. Research covers UTI prevention, Urinary tract health, Antioxidant protection and 1 more areas. The overall evidence strength is rated as Strong.

How strong is the evidence for Cranberry Extract?

The evidence is currently rated as "Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (4 human studies), and reported outcomes.

What health goals has Cranberry Extract been studied for?

Cranberry Extract has been researched for: UTI prevention, Urinary tract health, Antioxidant protection, Cardiovascular health. Each area has its own body of evidence which you can explore in the study breakdowns above.

Are the studies on Cranberry Extract based on human trials?

Yes, 4 out of 120 studies are human trials. Human trials carry more weight in our evidence scoring system.